News
The Impact of New Medicines in the NHS: 70 Years of Innovation
14 August 2018
This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.
Opportunity Costs of New Health Care Technologies: A Research Agenda
8 August 2018
A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.
Presentations from EuHEA 2018
2 August 2018
OHE staff recently attended the European Health Economics Association (EuHEA) 2018 conference. In this blog post, we share a selection of our presentations. Establishing a Reasonable…
New Journal Article: Directly Eliciting Personal Utility Functions
31 July 2018
A new article in the European Journal of Health Economics describes the ‘personal utility functions’ approach to valuing health
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?
Presentations from AES and PROMs Summer 2018
24 July 2018
OHE staff recently attended AES and PROMs Summer 2018 conferences. In this blog post, we share a selection of our presentations.
OHE’s Paula Lorgelly Elected as HESG Joint National Organiser
23 July 2018
Paula Lorgelly and Bruce Hollingsworth (Lancaster University) have taken the role of joint National Organisers for the Health Economists’ Study Group.
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?
Presentations from ISPOR and HTAi 2018
12 July 2018
OHE staff recently attended ISPOR and HTAi international conferences. In this blog post, we share a selection of our presentations.